Developing Novel Therapies for Fibrosis

开发纤维化新疗法

• 批准号: nhmrc : GNT1041766
• 负责人: A/Pr Chrishan Samuel
• 金额: $ 59.08万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-novel-therapies-fibrosis/1344382
• 关键词: Developing; Novel; Therapies; Fibrosis

I am a matrix biologist determining the molecular mechanisms and novel therapeutic targets for fibrosis (tissue scarring). In particular, my research, which has a strong translational focus, is involved with elucidating the anti-fibrotic potential of the relaxin peptide-hormones (either alone or as an adjunct therapies to existing/other novel treatments) – as a means of developing therapeutic strategies for the treatment of cardiac and renal fibrosis.

我是一名基质生物学家，确定纤维化（组织瘢痕形成）的分子机制和新的治疗靶点。特别是，我的研究，这具有很强的翻译重点，涉及阐明松弛素肽激素的抗纤维化潜力（单独或作为现有/其他新疗法的辅助疗法）-作为开发治疗心脏和肾脏纤维化的治疗策略的一种手段。